These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21178622)

  • 41. Comment on: The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks.
    Deane A; Young R
    J Antimicrob Chemother; 2008 Jan; 61(1):227; author reply 227-8. PubMed ID: 17981832
    [No Abstract]   [Full Text] [Related]  

  • 42. Cisapride and intestinal dysmotility: the final word?
    Craig JS
    Biol Neonate; 2005; 88(4):276-7. PubMed ID: 16113521
    [No Abstract]   [Full Text] [Related]  

  • 43. [On the possibility of using prokinetics in gastroenterology].
    Sheptulin AA; Vize-Khripunova MA
    Klin Med (Mosk); 2010; 88(5):19-22. PubMed ID: 21089451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Mechanism and clinical application of erythromycin as a gastrointestinal prokinetic agent in children].
    Yang Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):102-4. PubMed ID: 18289489
    [No Abstract]   [Full Text] [Related]  

  • 45. Influence of erythromycin on establishment of feeding in preterm infants: observations from a randomised controlled trial.
    Stenson BJ; Middlemist L; Lyon AJ
    Arch Dis Child Fetal Neonatal Ed; 1998 Nov; 79(3):F212-4. PubMed ID: 10194995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The risks and benefits of cisapride.
    Cairns P
    Arch Dis Child; 1999 May; 80(5):493. PubMed ID: 10523247
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of hyperinsulinaemia on erythromycin-induced gallbladder and gastric motility in normal subjects.
    Cordoni MC; Distrutti E; Vermigli C; Marino C; Bottini P; Bosso R; Scionti L
    Diabetes Nutr Metab; 2004 Feb; 17(1):72-5. PubMed ID: 15163131
    [No Abstract]   [Full Text] [Related]  

  • 48. [Prokinetic agents (prokinetics) in the treatment of motor disorders of the gastrointestinal tract].
    Frol'kis AV
    Ter Arkh; 1998; 70(2):69-72. PubMed ID: 9551580
    [No Abstract]   [Full Text] [Related]  

  • 49. Successful treatment of enterocutaneous fistula in a premature newborn by using octreotide.
    Büyükyavuz I; Karnak I; Yiğit S; Tanyel FC
    Turk J Pediatr; 2004; 46(3):289-91. PubMed ID: 15503489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ion channels as targets for treatment of gastrointestinal motility disorders.
    Farrugia G
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():135. PubMed ID: 18924455
    [No Abstract]   [Full Text] [Related]  

  • 51. Erythromycin in neonatal postoperative intestinal dysmotility.
    Simkiss DE; Adams IP; Myrdal U; Booth IW
    Arch Dis Child Fetal Neonatal Ed; 1994 Sep; 71(2):F128-9. PubMed ID: 7979468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benefits of a standardised feeding regimen during a clinical trial in preterm neonates.
    Patole SK; Kadalraja R; Tuladhar R; Almonte R; Muller R; Whitehall JS
    Int J Clin Pract; 2000 Sep; 54(7):429-31. PubMed ID: 11070566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are the stool characteristics of preterm infants affected by infant formulas?
    Duman N; Utkutan S; Ozkan H; Ozdoğan S
    Turk J Pediatr; 2000; 42(2):138-44. PubMed ID: 10936980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of prophylactic oral erythromycin to improve enteral feeding tolerance in preterm infants: a randomised controlled study.
    Mohammadizadeh M; Ghazinour M; Iranpour R
    Singapore Med J; 2010 Dec; 51(12):952-6. PubMed ID: 21221501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do antibiotics improve neonatal outcomes in preterm premature rupture of membranes (PPROM)?
    Grier M; Weston J; Xu Y; Patil A; Epling J
    J Fam Pract; 2001 Jul; 50(7):626. PubMed ID: 11485716
    [No Abstract]   [Full Text] [Related]  

  • 56. Erythromycin and motilin as gastrointestinal prokinetic agents.
    Asai T
    Eur J Anaesthesiol; 1997 Jan; 14(1):3-6. PubMed ID: 9049551
    [No Abstract]   [Full Text] [Related]  

  • 57. Erythromycin as a gastrointestinal prokinetic agent.
    Bradley C
    Intensive Crit Care Nurs; 2001 Apr; 17(2):117-9. PubMed ID: 11817442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Gastrointestinal motility disorders and drugs: cholinergic, anticholinergic, adrenergic, antiadrenergic and prokinetic drugs (part I)].
    Jovanović-Mićić D; Janković S; Beleslin DB
    Srp Arh Celok Lek; 1994; 122(1-2):50-4. PubMed ID: 17972806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of gut peptide receptor agonists and antagonists in gastrointestinal diseases.
    Maton PN; Jensen RT
    Gastroenterol Clin North Am; 1992 Sep; 21(3):551-66. PubMed ID: 1355466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study on effects of 14- and 16-membered macrolides on gastrointestinal motility in unanaesthetized dogs.
    Nakayoshi T; Izumi M; Shinkai S; Fujita M
    Drugs Exp Clin Res; 1988; 14(5):319-25. PubMed ID: 3265375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.